For patients with COVID-19 being treated with intermediate- or full-dose enoxaparin, have anti-Xa levels been checked? If so, have higher-than-expected anti-Xa levels been found?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on March 10, 2021
 
Moderator: Gina Hurst, MD
Speakers: Brad Johnson, MD; Kelsey L. Ohman, PharmD, BCCCP; Adam Schlichting, MD, MPH
 
This educational activity was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (grant number 1 NU50CK000566-01-00). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). Its contents do not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.

Estimated Time: 2mins 22secs